Moximed develops and manufactures implantable devices for knee osteoarthritis treatment. The company focuses on providing outpatient treatment options that aim to improve quality of life for patients with knee pain who are not yet candidates for knee replacement surgery.

Moximed

Runway Growth Capital

New Enterprise Associates

GBS Ventures

Vertex Ventures

Morgenthaler Ventures

Advent Life Sciences

Future Fund

Gilde Healthcare

Ischyros New York

#NEWS: We’ve secured #SeriesD financing for $91 million: https://lnkd.in/eYh3WgxQ 

Funds will be used to accelerate U.S. commercialization of the MISHA® Knee System. 
 
We’re grateful for the support from lead investor Elevage Medical Technologies, new investors Cormorant Asset Management, LP, Warren Point Capital, and existing investors New Enterprise Associates (NEA), Future Fund, Advent Life Sciences, Glide Healthcare, Vertex Ventures HC, GBS Venture Partners, and Morgenthaler.
 
#Financing #MedTech #MoveToMISHA #KneeOA #Orthopedics #SportsMedicine

Join us in congratulating Dr. Alexander Golant of NYU Langone Health on making the #MoveToMISHA! 👏
 
“The MISHA® Knee System is an excellent option for the right patient,” he said. “It just makes sense in so many ways – avoidance of premature arthroplasty, simple recovery process, and potential for significant pain relief and improvement in function, even with moderate and high-intensity activities. I am excited to have this new instrument in my surgical toolbox.”
 
#MovedToMISHA #Orthopedics #SportsMedicine #KneeOA

We are still buzzing from an exciting #AOSSM2024 last week! 

• Thursday morning Dr. Andreas Gomoll and Dr. David Diduch led a jampacked cadaver lab demonstration

• Thursday evening Dr. Sabrina Strickland and Dr. Cassandra Lee led an exceptional dinner program with The FORUM, a national group of female Orthopedic Surgeons

• Friday morning Dr. Alexander K. Meininger, M.D. FAAOS and his patient, Joe (7-months post-op), led the Moximed team on a leisurely 4-mile run through Denver, and both of them were interviewed by the Denver NBC affiliate KUSA-TV, 9NEWS 

• Friday morning Dr. jason dragoo, Dr. Seth L. Sherman and Dr. David Diduch shared their knowledge and expertise during a presentation in the exhibit hall

We sincerely appreciate the support of the American Orthopaedic Society for Sports Medicine and all of the early adopters who helped educate surgeons interested in treating patients with medial #KneeOA with an implantable shock absorber. 

#MOVEtoMISHA

Christopher Kaeding Eric McCarty Peter A Indelicato MD Moximed OLC Education and Conference Center

“Every new medical technology begins with innovators who dare to challenge the status quo, and this spirit of moxie is something I will continue to push for in this role.”
 
Christopher Gleason, new President and CEO of Moximed, shares his thoughts as this new chapter begins. Check out his article below. 👇
 
#SportsMedicine #Orthopedics #MoveToMISHA #Leadership #MedTech

https://lnkd.in/eQPa97aa

Dr. Seth L. Sherman of Stanford Health Care is among the first surgeons in the country who #MovedToMISHA! 🙌 
 
“The MISHA® Knee System is a game changer for my ‘tweener’ population with medial knee osteoarthritis - too young and active for joint replacement, but poor candidates for other joint preservation strategies. I am excited to offer this generational technology to many more patients over time.”
 
Learn more about MISHA: https://moximed.com/misha/
 
#MoveToMISHA #KneeOA #Orthopedics #SportsMedicine

Congratulations to Justin Saliman, MD on joining the first group of surgeons in the country who #MovedToMISHA! 👏 
 
“We must set our sights beyond temporary fixes. The true aim lies not in merely pushing problems ahead but in safeguarding the very joints that carry us forward. With the MISHA® Knee System, my OA patients are not just able to preserve their knee joint, but they’re able to quickly get back to the activities they love.”
 
Find out more about MISHA: https://moximed.com/misha/
 
#MoveToMISHA #KneeOA #Orthopedics #SportsMedicine

Metric
Company Name	Moximed
Symbol
MSH ID	COM:MOXIMED
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	US
Stage	Series D
Employee Count	51
Website	moximed.com
LinkedIn	moximed
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	22.26K
Web Traffic Growth	0.28
Valuation
Raised Capital	61M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MOXIMED

Moximed

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue